Expression of interest and payment now open

Explore current developments in science and technology at Griffith University.

The Cutting Edge Science Professional Learning Day aims to provide engaging lectures and workshops by Griffith University academics, research scientists and science leaders to explore current developments in science, technology, engineering and mathematics while enhancing student engagement and learning outcomes in a classroom setting.

Cutting Edge Information

The Cutting Edge for Teachers Professional Learning Day aims to provide engaging lectures and workshops to explore current developments in science, technology, engineering and mathematics. The 2025 event intends to engage over 150 teachers from across Queensland with an exciting array of workshops and a dazzling keynote.

Date: 26 November 2025

Griffith University Gold Coast

Express your interest

Keynote of 2025: Prof Mark von Itzstein

Professor von Itzstein AO was the founding Director of Griffith University’s Institute for Glycomics in 2000.  Professor von Itzstein AO has a major research effort in the area of drug discovery, with a carbohydrate-based drug candidate against sepsis in phase 2 human clinical trials. He has international standing in glycoscience and drug discovery particularly in the area of anti-infective drug discovery.   Professor von Itzstein led the team responsible for the design, synthesis and biological evaluation of the anti-influenza drug, Relenza®, which has been approved for the treatment of influenza worldwide since 1999. This discovery is considered to be a significant outcome and flagship in glycotherapeutic and antiviral drug development in the last century and has further consolidated the world platform of using carbohydrates as drugs and carbohydrate-recognising proteins as drug discovery targets. Professor von Itzstein AO is currently a Distinguished Professor and his current research interests in drug discovery are focused on influenza, parainfluenza and other viruses, drug-resistant bacteria and cancer.

Any questions?

For more information contact us